Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan + Palbociclib vs Belzutifan in Advanced Renal Cell Carcinoma
2023-504963-17-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing Belzutifan + Palbociclib with Belzutifan monotherapy (2 arms). Primary endpoints: Part 1 - Number of Participants Who Experience at Least One Dose-limiting Toxicity (DLT), Part 1 - Number of Participants Who Experience at Least One Adverse Event (AE) and 2 more. Started Jul 2024; status: completed.
02
Drugs
belzutifanpalbociclib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2023-504963-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504963-17-00.